{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06200181",
            "orgStudyIdInfo": {
                "id": "2023-0492"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-11092",
                    "type": "OTHER",
                    "domain": "NCI-CTRP Clinical Registry"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial",
            "officialTitle": "Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "effect-of-olanzapine-on-opioid-craving-and-misuse-among-patients-receiving-opioids-for-cancer-related-pain-a-pilot-double-blind-randomized-control-trial"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-11-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-11-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-28",
            "studyFirstSubmitQcDate": "2023-12-28",
            "studyFirstPostDateStruct": {
                "date": "2024-01-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "To learn about the effectiveness of taking the antipsychotic medication olanzapine to help lower opioid craving.",
            "detailedDescription": "Primary Objective To determine the effect of olanzapine on opioid craving among patients receiving opioids for cancer pain (Opioid Craving Scale; Opioid Craving Visual Analogue Scale, change from baseline)\n\nSecondary Objective To determine the effect of olanzapine on opioid misuse among patients receiving opioids for cancer pain (Current Opioid Misuse Measure, change from baseline)\n\nExploratory Objective\n\n* To estimate the effect of olanzapine and placebo on the amount of opioid use among patients receiving opioids for cancer pain (morphine equivalent daily dose)\n* To determine the effect of olanzapine and placebo on pain intensity among patients receiving opioids for cancer pain (Brief Pain Inventory)\n* To determine the effect of olanzapine and placebo on overall symptom burden among patients receiving opioids for cancer pain (ESAS symptom Distress Score)\n* To estimate the differences between the olanzapine and placebo effects on opioid craving and misuse measures (Opioid Craving Scale, Opioid Craving Visual Analogue Scale, Current Opioid Misuse Measure)\n* To determine the adverse effects of olanzapine and placebo among patients receiving opioids for cancer pain (National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0)"
        },
        "conditionsModule": {
            "conditions": [
                "Misuse, Opioid"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 87,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take a lower dose of olanzapine every day for Days 1-7 and then a higher dose every day for the next 3 weeks",
                    "interventionNames": [
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "Arm 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will take the lower dose of olanzapine every day for 4 weeks.",
                    "interventionNames": [
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "Arm 3",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will take a placebo every day for 4 weeks.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Olanzapine",
                    "description": "Given by PO",
                    "armGroupLabels": [
                        "Arm 1"
                    ],
                    "otherNames": [
                        "Zypreza"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olanzapine",
                    "description": "Given by PO",
                    "armGroupLabels": [
                        "Arm 2"
                    ],
                    "otherNames": [
                        "Zypreza"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Given by PO",
                    "armGroupLabels": [
                        "Arm 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and adverse events (AEs",
                    "description": "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",
                    "timeFrame": "Through study completion; an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosis of head and neck cancer\n3. Receiving chronic opioid therapy (\u2265 30 days)\n4. Active use of opioids within the past 7 days\n5. Opioid misuse behavior (COMM score \u2265 9/68)\n6. ECOG performance status \u2265 2/4\n7. Ability to communicate in English\n8. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Contraindications to, or allergic to, olanzapine\n2. Current use of any antipsychotic medication (e.g. quetiapine, haloperidol, risperidone, etc.)\n3. History of OUD or other substance use disorders, except marijuana\n4. History of formal psychiatric diagnoses (e.g. bipolar disorder, schizophrenia, major depressive disorder, or anorexia nervosa)\n5. Hepatic insufficiency (defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 3 times the highest normal value, or total bilirubin \\>1.5 times the highest normal value) within the past month\n6. History of uncontrolled Diabetes Mellitus or hyperglycemia (fasting \u2265 200 mg/dL) within the past month\n7. History of seizure disorder or neuroleptic malignant syndrome\n8. History of cardiac disease (e.g. coronary artery disease, congestive heart failure)\n9. (Females only) Known pregnancy, as communicated to study personnel by clinicians; females of childbearing potential will receive advice to use methods of contraception per usual care.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joseph Arthur, MD",
                    "role": "CONTACT",
                    "phone": "(713) 794-1649",
                    "email": "jaarthur@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Joseph Arthur, MD",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph Arthur, MD",
                            "role": "CONTACT",
                            "phone": "713-794-1649",
                            "email": "jaarthur@mdanderson.org"
                        },
                        {
                            "name": "Joseph Arthur, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "MD Anderson Cancer Center",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000072716",
                    "term": "Cancer Pain"
                },
                {
                    "id": "D000009293",
                    "term": "Opioid-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010146",
                    "term": "Pain"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000079524",
                    "term": "Narcotic-Related Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M1091",
                    "name": "Cancer Pain",
                    "asFound": "Cancer-related Pain",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12244",
                    "name": "Opioid-Related Disorders",
                    "asFound": "Misuse, Opioid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M2057",
                    "name": "Narcotic-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077152",
                    "term": "Olanzapine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M1675",
                    "name": "Olanzapine",
                    "asFound": "Field",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                }
            ]
        }
    },
    "hasResults": false
}